If you have been reading about ipamorelin and want a single page that covers the useful parts, this is it: definitions, context, how it is studied, and the questions that come up repeatedly.
Last reviewed on 2026-03-08. Where a claim depends on a specific study, the study is described rather than over-claimed.
At the molecular level, ipamorelin acts as an agonist at the growth hormone secretagogue receptor, also called the ghrelin receptor or GHS-R1a. Binding to this receptor on pituitary somatotroph cells triggers a signaling cascade that leads to growth hormone release. The effect is mediated through phospholipase C and calcium mobilization rather than through the cyclic AMP pathway used by growth hormone releasing hormone. The two pathways are complementary, and combined stimulation produces a larger response than either alone.
Compared with other secretagogues such as GHRP-2, GHRP-6, and hexarelin, ipamorelin is described as more selective. Published animal work reports little or no increase in adrenocorticotropic hormone, cortisol, or prolactin at doses that release growth hormone. This selectivity is the property most often cited in the research literature. Whether the same profile holds across species and dosing schedules remains an open question, since human data are limited and come largely from small studies.
Ipamorelin is a synthetic pentapeptide that belongs to the growth hormone secretagogue family. Its sequence is Aib-His-D-2-Nal-D-Phe-Lys-NH2, and its molecular mass is approximately 711.9 daltons. The compound was described in the late 1990s by researchers seeking molecules that release growth hormone with fewer side effects than earlier secretagogues. It is a laboratory and research compound, not an approved medicine in most jurisdictions.
Published discussion of this compound is uneven. Some references describe it as a tool for probing growth hormone regulation, while others focus on analytical characterization or on comparisons with related secretagogues. Statements about selectivity, half-life and potency often trace back to a small number of original reports that later authors cite secondhand. Readers evaluating a claim should therefore check whether a figure reflects a direct measurement or a repeated citation, and whether the underlying study was conducted in animals, in isolated cells or in human volunteers.
Identity and purity assessment for a research peptide of this kind typically combines reversed-phase high-performance liquid chromatography with mass spectrometry. The chromatographic run separates related impurities and yields a purity percentage, while electrospray ionization or matrix-assisted laser desorption mass spectrometry confirms the expected molecular mass. Amino acid analysis or tandem mass spectrometry sequencing can add confidence when material is intended for quantitative work. Laboratories differ in how they calculate and report purity, so figures from different sources are not always directly comparable.
Lyophilized material is generally stored cold and dry, with desiccant, and protected from light. In solution the peptide is more vulnerable: the histidine side chain can oxidize, and repeated freeze-thaw cycles promote aggregation and loss of material to container surfaces. A mildly acidic aqueous buffer is often used for short-term handling because it limits several degradation routes. Accurate prediction of long-term stability under a given set of conditions is difficult, and published stability data remain sparse.
| Property | Value | Notes |
|---|---|---|
| Chemical class | Synthetic pentapeptide | Growth hormone secretagogue family |
| Molecular mass | Approximately 711.9 Da | Free base, calculated value |
| Receptor target | GHS-R1a, the ghrelin receptor | Agonist activity reported |
| Sequence | Aib-His-D-2-Nal-D-Phe-Lys-NH2 | C-terminal amide |
| Reported selectivity | Little change in ACTH, cortisol, prolactin | Based mainly on animal data |
Storage recommendations for ipamorelin usually focus on temperature, moisture, and light. Lyophilized powder is typically held at or below minus twenty degrees Celsius in a desiccated container protected from light. Reconstituted solutions are often aliquoted and stored at minus eighty degrees Celsius to reduce repeated freeze-thaw cycles, which can promote aggregation or degradation. The optimal buffer and pH depend on the specific assay, and no single condition applies to every experimental context. Peptide stability should be assessed with time-point measurements rather than assumed from general handling rules.
In the scientific literature, ipamorelin appears mainly in preclinical studies, receptor binding assays, and reviews of growth hormone secretagogues. Authors often discuss its selectivity profile alongside limitations such as small sample sizes, short study durations, and differences between species. Some papers examine pharmacokinetics and clearance, but human data are limited and not sufficient to define general clinical effects. Regulatory discussion treats the compound as an investigational or research substance rather than an approved therapy in most jurisdictions. Open questions include oral bioavailability, long-term endocrine effects, and whether selectivity observed in animals persists in humans.
Ipamorelin is a synthetic pentapeptide that belongs to the growth hormone secretagogue class of compounds. Its sequence is Aib-His-D-2-Nal-D-Phe-Lys-NH2, a structure that differs from natural ghrelin in length and in the presence of non-natural amino acid residues. Early laboratory work described it as a comparatively selective agent that stimulates growth hormone release with limited effect on other pituitary hormones. The compound is supplied as a lyophilized solid for research use and has no identified natural source in the body.
Activity is mediated mainly through the growth hormone secretagogue receptor, now generally called the ghrelin receptor or GHS-R1a. Binding at this G-protein-coupled receptor triggers phospholipase C signaling, calcium mobilization, and release of growth hormone from pituitary somatotrophs. Reports describe less pronounced stimulation of adrenocorticotropic hormone and prolactin compared with earlier secretagogues such as hexarelin or GHRP-6. Selectivity figures vary between assay systems, so the degree of separation from other secretagogues is an area of ongoing comparison rather than a fixed constant.
Ipamorelin is a synthetic pentapeptide first described in the 1990s by researchers at Novo Nordisk during a program to develop selective growth hormone secretagogues. Its sequence is Aib-His-D-2-Nal-D-Phe-Lys-NH2, incorporating two non-natural residues, alpha-aminoisobutyric acid and D-2-naphthylalanine. The C-terminus is amidated, and the material is supplied as a white lyophilized powder. The molecular formula is C38H49N9O5 and the monoisotopic mass is approximately 711.85 daltons. The short chain and modified residues give it greater resistance to enzymatic degradation than many larger peptide hormones.
At the molecular level, ipamorelin acts as an agonist at the growth hormone secretagogue receptor type 1a, the same G protein-coupled receptor that binds ghrelin. Receptor activation couples to Gq/11 signaling, raising intracellular calcium through inositol trisphosphate and diacylglycerol, which in turn promotes exocytosis of growth hormone from pituitary somatotroph cells. Ipamorelin binds this receptor with high affinity and shows weak activity at other secretagogue-related targets in vitro. Its action requires the intact receptor and is not reversed by growth hormone-releasing hormone antagonists.
Compared with earlier growth hormone secretagogues such as GHRP-6 and hexarelin, ipamorelin has been reported to produce less stimulation of adrenocorticotropic hormone, cortisol, and prolactin in animal and early human studies. This selectivity is usually attributed to differences in receptor subtype interactions and to the tissue distribution of the receptor. Effects on appetite appear weaker than those of ghrelin itself, although the supporting evidence base is small. Whether these differences produce a distinct clinical profile remains an open question, since controlled human trials are limited.
Before the production of tequila or mezcal, pulque had been brewed from agave sap for thousands of years. Pulque is fermented, not distilled. The distillation technology to produce mezcal from agave heart juice was first introduced by Filipino sailors and migrants into the coastal regions of what was then Nueva Galicia (present-day Aguascalientes, Colima, Guanajuato, Jalisco, Nayarit, and Zacatecas). Mezcal distillation spread into the highland valleys of Amatitán, Tequila, Magdalena, and El Arenal in the mid-1700s. The distinctive mezcal produced in these regions became known as "tequila". Spain's King Carlos IV granted the Cuervo family the first license to commercially make tequila. Don Cenobio Sauza, founder of Sauza Tequila and Municipal President of the Village of Tequila from 1884 to 1885, was the first to export tequila to the United States. The first tequila distillery in the United States was opened in 1936 in Nogales, Arizona by Harry J. Karns, former Arizona state senator and Nogales Mayor. The Mexican government declared the term "tequila" to be its intellectual property in 1974.
=== Australia === Dialysis is provided without cost to all patients through Medicare, with 75% of all dialysis being administered as haemodialysis to patients three times per week in a dialysis facility. The Northern Territory has the highest incidence rate per population of haemodialysis, with Indigenous Australians having higher rates of Chronic Kidney Disease and lower rates of functional kidney transplants than the broader population. The remote Central Australian town of Alice Springs, despite having a population of approximately 25000, has the largest dialysis unit in the Southern Hemisphere. Many people must move to Alice Springs from remote Indigenous communities to access health services such as haemodialysis, which results in housing shortages, overcrowding, and poor living conditions.
Usual interstitial pneumonia (UIP) is a form of lung disease characterized by progressive scarring of both lungs. The scarring (pulmonary fibrosis) involves the pulmonary interstitium (the supporting framework of the lung). UIP is thus classified as a form of interstitial lung disease.
=== Juvenile breast hypertrophy === When gigantomastia occurs in pubescent females, the medical condition is known as juvenile macromastia or juvenile gigantomastia and sometimes as virginal breast hypertrophy or virginal mammary hypertrophy although the term virginal is now considered misleading and outdated. Along with the excessive breast size, other symptoms include red, itchy lesions and pain in the breasts. A diagnosis is made when an adolescent's breasts grow rapidly and achieve great weight, usually soon after their first menstrual period. Some doctors suggest that the rapid breast development occurs before the onset of menstruation. Some adolescents with juvenile breast hypertrophy experience breast growth at a steady rate for several years, after which the breasts rapidly develop exceeding normal growth. Some adolescent females experience minimal or negligible breast growth until their breasts suddenly grow very rapidly in a short period of time. This may cause considerable physical discomfort. Individuals with JBH often experience an excessive growth of their nipples as well. In severe cases of JBH, clitoromegaly occurs. At the onset of puberty, some females who have experienced little or no breast development can reportedly reach three or more cup sizes within a few days (see below). As of 1992, 70 cases of juvenile breast hypertrophy had been reported.
== Epidemiology == BPD has a point prevalence of 1.6% and a lifetime prevalence of 5.9% of the global population. Within clinical settings, the occurrence of BPD is 6.4% among urban primary care patients, 9.3% among psychiatric outpatients, and approximately 20% among psychiatric inpatients. Utilization of healthcare resources by individuals with BPD is high. Up to half may show significant improvement in their condition, resulting in ineligibility for diagnosis of BPD, following a ten-year period with appropriate treatment. Regarding gender distribution, women are diagnosed with BPD three times more frequently than men in clinical environments. Nonetheless, epidemiological research in the United States indicates no significant gender difference in the lifetime prevalence of BPD within the general population. Feminist scholars argue that the diagnosis is disproportionately applied to women, particularly survivors of childhood sexual abuse, and that it pathologizes the understandable emotional and relational responses to gendered violence. The relationship between BPD and ethnicity continues to be ambiguous, with divergent findings reported in the United States. The overall prevalence of BPD in the U.S. prison population is thought to be 17%. Sexual minorities (i.e., lesbian, gay, bisexual) are up to 3.82 times more likely to be diagnosed with BPD and gender minorities (i.e., transgender and gender diverse) are up to 4.05 times more likely to be diagnosed.
Sources: en.wikipedia.org
== Career == Sur joined the faculty of the Department of Brain and Cognitive Sciences at the Massachusetts Institute of Technology (MIT) in 1986. In 1993, he was named professor of Neuroscience, and in 1997, head of the Department of Brain and Cognitive Sciences. He is currently the Newton Professor of Neuroscience and director of the Simons Center for the Social Brain at MIT. Sur is a pioneer in technology development for analyzing the function and structure of neurons and synapses in the live brain, and the study of brain plasticity and its mechanisms. His research involves experimental and computational approaches to study developmental plasticity in the developing brain, and dynamic changes in mature cortical networks during learning and information processing. His laboratory investigates fundamental principles governing how networks of the cerebral cortex are wired during development and are dynamically reorganized during learning. His group's discoveries have provided foundational concepts of how cortical circuits process information underlying perception, cognition, and goal-directed action.
These values are much greater than the oxide's, but still a few orders of magnitude lower than those of pristine graphene. Recently, the synthetic protocol for graphite oxide was optimized and almost intact graphene oxide with a preserved carbon framework was obtained. Reduction of this almost intact graphene oxide performs much better and the mobility values of charge carriers exceeds 1000 cm2/Vs for the best quality of flakes. Inspection with the atomic force microscope shows that the oxygen bonds distort the carbon layer, creating a pronounced intrinsic roughness in the oxide layers which persists after reduction. These defects also show up in Raman spectra of graphene oxide. Large amounts of graphene sheets may also be produced through thermal methods. For example, in 2006 a method was discovered that simultaneously exfoliates and reduces graphite oxide by rapid heating (>2000 °C/min) to 1050 °C. At this temperature, carbon dioxide is released as the oxygen functionalities are removed and it explosively separates the sheets as it comes out. The temperature of reduction is important for the oxygen content of the final product, with higher degree of reduction for higher reduction temperatures. Exposing a film of graphite oxide to the laser of a LightScribe DVD has also revealed to produce quality graphene at a low cost. Graphene oxide has also been reduced to graphene in situ, using a 3D printed pattern of engineered E. coli bacteria. Coupling of graphene oxide with biomolecules such as peptide, proteins and enzymes enhances its biomedical applications.
After details of past social media posts made by two Reform UK candidates, Lee Bunker and Angela Begbie-Carter, are reported in the media, the party releases a statement in which it says candidates are free to express views that "are not shared by all their party colleagues" as they are not "political zombies". Secret government files seen by BBC News show work has been underway with consultants since January to limit "severe implications" to essential IT services by lining up alternative providers after Atos, the UK subsidiary of which has contracts for NHS records and disability benefit claims, is more than £3bn in debt and undergoing restructuring. Sinn Féin launches its 2024 election manifesto, which includes plans for the transfer of fiscal powers from Westminster to Stormont and the creation of an all-Ireland national health service. Businessman Zia Yusuf donates an undisclosed amount of money, but reported to be several thousand pounds, to Reform UK, saying the UK has "lost control of our borders". The Workers Party of Britain launches its election manifesto, with promises to improve "poverty pay" and provide more social housing. BBC News reports that Laura Saunders, the Conservative candidate for Bristol North West, has become the second Conservative candidate to face an investigation by the Gambling Commission over betting on the date of the general election. It is subsequently reported that her husband, Tony Lee, the Conservative Party's campaigns director, is also being investigated by the Commission.
Živojinović (nicknamed Bata) was born in the village of Koraćica under the Kosmaj mountain near Mladenovac, at the time Kingdom of Yugoslavia (now Serbia). His father, Dragoljub, was an official and his mother Tiosava was a housewife. He had two sisters, Stanka and Nada, and grew up in a patriarchal household. A conflict between Dragoljub and the Chetniks during World War II forced the family to move to Belgrade. The family lived in Crveni Krst. Young Bata often went with his friends to the cinema, which sparked his interest in acting. Loitering around the "20th October" cinema, he watched AKUD Branko Krsmanović, a Belgrade troupe, through the window for several days until he was welcomed inside. There he befriended Soja Jovanović, instrumental in the developing of Bata's love for acting, Rade Marković, Olivera Marković, Mića Tomić, and Bata Paskaljević. After graduating from acting schools in Niš and Novi Sad, he enrolled at the Drama Academy in Belgrade.
Sources: en.wikipedia.org
== Subfamily B3 == Subfamily B3 includes Methuselah and other Drosophila proteins. Other than the typical seven-transmembrane region, characteristic structural features include an amino-terminal extracellular domain involved in ligand binding, and an intracellular loop (IC3) required for specific G-protein coupling.
Cerebral folate deficiency (CFD) is a syndrome in which concentrations of 5-methyltetrahydrofolate (5-MTHF) are low in the brain as measured in the cerebral spinal fluid despite being normal in the blood. Symptoms typically appear at about 5 to 24 months of age. Without treatment there may be poor muscle tone, trouble with coordination, trouble talking, and seizures. One cause of cerebral folate deficiency is a mutation in a gene responsible for folate transport, specifically FOLR1. This is inherited in an autosomal recessive manner. Other causes include Kearns–Sayre syndrome,, autoantibodies to the folate receptor FOLR1, and metabolic errors such as 5,10-methenyltetrahydrofolate synthetase deficiency. For people with the FOLR1 mutation, even when the systemic deficiency is corrected by folate, the cerebral deficiency remains and must be treated with folinic acid. Success depends on early initiation of treatment for lengthy periods. Fewer than 20 people with the FOLR1 defect have been described in the medical literature.
The chordae tendineae (sing.: chorda tendinea) or tendinous cords, colloquially known as the heart strings, are inelastic cords of fibrous connective tissue that connect the papillary muscles to the tricuspid valve and the mitral valve in the heart.
Sources: en.wikipedia.org
Ipamorelin is a synthetic pentapeptide that stimulates growth hormone release by activating the ghrelin receptor. It is handled as a research tool rather than as a licensed therapeutic product. Its short chain length makes it comparatively simple to synthesize and analyze.
Both bind the same receptor, but ghrelin is a 28-amino-acid hormone with roles in appetite and energy balance. Ipamorelin is a much smaller synthetic peptide selected for growth hormone release with limited effect on appetite signaling in animal models. The full overlap between their effects is not completely mapped.
Most published data come from animal studies and a small number of human trials. Findings on growth hormone release are reasonably consistent, while long-term effects and direct comparisons with other secretagogues remain incompletely studied. Open questions include duration of action across different populations.
Reversed-phase liquid chromatography is standard for purity, and mass spectrometry is standard for identity. Amino acid analysis is used when quantitative composition matters. No single technique answers every question, so laboratories usually combine two or three.